Obatoclax mesylate, a pan-Bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer

Alberto Chiappori, Charles Williams, Donald W. Northfelt, John W. Adams, Shakun Malik, Martin J. Edelman, Peter Rosen, David A. Van Echo, Mark S. Berger, Eric B. Haura

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint Dive into the research topics of 'Obatoclax mesylate, a pan-Bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences